University Of Massachusetts Medical School

The University of Massachusetts Medical School's Grants and Contracts Administration Division, operating as UMMS, is a state government entity and 1862 Land Grant institution that delivers comprehensive medical inpatient and outpatient services, specialized surgical procedures, biomedical research, and clinical operations to federal agencies as a prime contractor (93% of recent awards) and as a subcontractor on research and clinical projects. UMMS competes in full-and-open federal procurement across a broad federal footprint concentrated in civilian correctional healthcare and biomedical research; the institution holds no SBA set-aside certifications and operates without small-business reserve restrictions.

UMMS's customer concentration is extreme and dual-peaked. The top two customers—the Department of Justice Bureau of Prisons facilities Federal Medical Center Devens and Federal Correctional Complex Butner—account for 41% of all recent awards. FMC Devens alone represents 735 awards valued at $430.5 million combined potential value, and Federal Correctional Complex Butner accounts for 381 awards worth $894.2 million. These two Bureau of Prisons facilities together drive approximately 69% of UMMS's combined potential value across the portfolio. The remaining federal footprint spans biomedical research through the National Institutes of Health—the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institute of Neurological Disorders and Stroke, and National Institute on Aging among the leading research funders—with 658 NIH awards collectively carrying modest individual research grant values relative to the correctional healthcare base.

UMMS operates the majority of its Bureau of Prisons work through two foundational vehicles: a Blanket Purchase Agreement with Federal Correctional Complex Butner (DJBDEV2050705007 and related modifications) anchoring 842 task orders worth $489.1 million combined potential value, and an Indefinite Delivery Contract with Federal Medical Center Devens (15B20521D00000001) supporting 165 task orders valued at $76.2 million. Monthly purchase orders under these parent vehicles range from $894,000 to $3.5 million for comprehensive inpatient and outpatient medical services at Federal Correctional Complex Butner and from $350,000 to $2.5 million for outside hospital medical services at FMC Devens. Recent representative work includes a $3.28 million purchase order for comprehensive medical inpatient and outpatient services at Federal Correctional Complex Butner (October 2026, firm fixed price), a $1.3 million delivery order for outside hospital medical services at FMC Devens (September 2026), and a $319,500 delivery order from the Defense Health Agency for human cadavers and associated support services including logistics, technical support, and cremation (July 2026 through September 2028). The institution also holds a May 2026 Basic Ordering Agreement with the Bureau of Medicine and Surgery establishing a ten-year framework for clinical and research services at correctional and medical facilities through April 2036, with no obligated funds at establishment.

UMMS's federal biomedical research portfolio spans investigator-initiated competitive grants from multiple NIH institutes. Recent prime recipient work includes a $6.768 million Defense Health Agency award for female warfighter traumatic brain injury research (September 2026 through August 2030), a $2.001 million National Institute of General Medical Sciences project grant for CRISPR epigenome editing guide-RNA prioritization (September 2026 through August 2030), a $1.699 million Defense Health Agency grant investigating interferon-gamma signaling in neuroendocrine prostate cancer (July 2026 through June 2029), a $1.281 million National Heart, Lung, and Blood Institute award examining thromboxane generation as a biomarker and mediator of heart failure risk (July 2026 through March 2030), and a $1.06 million National Cancer Institute project grant for multi-targeted nanoparticle-based immunotherapy for pancreatic cancer (July 2026 through June 2031). UMMS also serves as recipient on cooperative agreements and training grants, including a $7.345 million National Institute of Nursing Research award for a multi-state longitudinal study of school-based health centers in pediatric asthma (April 2026 through March 2030) and a $1.038 million National Institute of Neurological Disorders and Stroke cooperative agreement for trivalent small interfering RNA therapeutics development for Huntington's disease (September 2026 through August 2028).

Activity has remained relatively stable at approximately 200 new awards per fiscal year (202 in FY2026, 226 in FY2025, 302 in FY2024), with 247 awards carrying ultimate completion dates within the next twenty-four months and combined potential value of $10.8 million facing recompete. SCI-reported invoicing of federal service contracts above the $150,000 threshold totaled $277.5 million across FY2022–FY2025, with FY2025 capturing $71.8 million across 20.7 FTEs. The SCI dataset shows median government-paid rates around $416.58/hr, with senior labor pricing through $482.97/hr at the 90th percentile, reflecting the specialized clinical and research expertise characteristic of an academic medical center. UMMS operates predominantly as a single-awardee prime with minimal subcontractor engagement on federal service contracts—0% average sub-hours share across prime contracts—though the institution serves as a named subcontractor on research and clinical projects led by other academic institutions and the University of Texas Health Science Center at San Antonio, Mayo Clinic, Duke University, Weill Medical College of Cornell University, and others.

UMMS's corporate structure places it as a subsidiary of the University of Massachusetts system; the medical school operates as a division of the larger state entity and shares parent status with Worcester City Campus Corporation within the UMass administrative hierarchy. The institution's federal contracting footprint reflects its dual mission as both a clinical healthcare provider and major biomedical research organization, with the Bureau of Prisons correctional healthcare base generating the majority of annual contract dollars while NIH-funded research establishes the institution's standing as a competitive extramural research recipient across multiple disease and life-science domains. Federal grant work covers basic science, translational research, clinical trials, training programs, and implementation science spanning immunology, neurology, oncology, cardiovascular disease, and pediatric health.